These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31603967)

  • 41. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
    Natt NK; Gupta A; Singh G; Singh T
    Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of cutaneous prostaglandin application on nail growth, nail brittleness, and intraocular pressure.
    Palmer DJ; Scheman A; Tanna AP; Bueno A
    J Cosmet Dermatol; 2018 Apr; 17(2):263-267. PubMed ID: 28681570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
    Chou SY; Chou CK; Kuang TM; Hsu WM
    Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ocular effects of topical 0.03% bimatoprost solution in normotensive feline eyes.
    Regnier A; Lemagne C; Ponchet A; Cazalot G; Concordet D; Gelatt KN
    Vet Ophthalmol; 2006; 9(1):39-43. PubMed ID: 16409244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the efficacy and safety of using 0.01% versus 0.03% bimatoprost for the treatment of eyebrow hypotrichosis: A randomized, double-blind, split-face, comparative study.
    Suchonwanit P; Harnchoowong S; Chanasumon N; Sriphojanart T
    J Cosmet Dermatol; 2020 Mar; 19(3):714-719. PubMed ID: 31317662
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension.
    Alm A; Grunden JW; Kwok KK
    J Glaucoma; 2011; 20(4):215-22. PubMed ID: 20520568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
    Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
    Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions.
    Campbell JH; Schwartz G; Labounty B; Kowalski J; Patel VD
    Curr Med Res Opin; 2013 Sep; 29(9):1201-9. PubMed ID: 23865686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of ocular surface side effects of topical travoprost and bimatoprost.
    Alagöz G; Bayer A; Boran C; Serin D; Kükner A; Elçioğlu M
    Ophthalmologica; 2008; 222(3):161-7. PubMed ID: 18497524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostaglandin-Associated Enophthalmos: An Observer-Masked Radiological Study of Patients Treated with Prostaglandin Drops to One Eye Only.
    Joganathan V; Aboelmagd SM; Eke T
    Orbit; 2015; 34(6):336-7. PubMed ID: 26540119
    [No Abstract]   [Full Text] [Related]  

  • 52. A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis.
    Yoelin SG; Fagien S; Cox SE; Davis PG; Campo A; Caulkins CA; Gallagher CJ
    Dermatol Surg; 2014 Oct; 40(10):1118-24. PubMed ID: 25229783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bimatoprost solution 0·03% topical application to the eyelid margin for the treatment of eyelash hypotrichosis.
    Arujuna NR; Topham EJ; Atkinson LR; George SM; Derrick EK; Farrant PB
    Br J Dermatol; 2016 Jun; 174(6):1416-7. PubMed ID: 26873623
    [No Abstract]   [Full Text] [Related]  

  • 54. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.
    Macky TA
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):605-10. PubMed ID: 21034177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.
    Smith S; Fagien S; Whitcup SM; Ledon F; Somogyi C; Weng E; Beddingfield FC
    J Am Acad Dermatol; 2012 May; 66(5):801-6. PubMed ID: 21899919
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of human ocular distribution of bimatoprost and latanoprost.
    Ichhpujani P; Katz LJ; Hollo G; Shields CL; Shields JA; Marr B; Eagle R; Alvim H; Wizov SS; Acheampong A; Chen J; Wheeler LA
    J Ocul Pharmacol Ther; 2012 Apr; 28(2):134-45. PubMed ID: 22136089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Latanoprost and periocular skin color changes.
    Wand M; Ritch R; Isbey EK; Zimmerman TJ
    Arch Ophthalmol; 2001 Apr; 119(4):614-5. PubMed ID: 11296032
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
    Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
    PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial.
    Brandt JD; VanDenburgh AM; Chen K; Whitcup SM;
    Ophthalmology; 2001 Jun; 108(6):1023-31; discussion 1032. PubMed ID: 11382623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.